Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.
Piñero F, Costentin C, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas A, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Duque SH, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Carrilho F, Cherqui D, Burra P, Van Vlierberghe H, Lai Q, Silva M, Rubinstein F, Duvoux C; collaborative group for HCC and liver transplantation; France; Latin America; Italy; Belgium. Piñero F, et al. Among authors: van vlierberghe h. JHEP Rep. 2022 Dec 5;5(2):100644. doi: 10.1016/j.jhepr.2022.100644. eCollection 2023 Feb. JHEP Rep. 2022. PMID: 36691474 Free PMC article.
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial.
Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM; Sirolimus Liver Conversion Trial Study Group. Abdelmalek MF, et al. Am J Transplant. 2012 Mar;12(3):694-705. doi: 10.1111/j.1600-6143.2011.03919.x. Epub 2012 Jan 10. Am J Transplant. 2012. PMID: 22233522 Free article. Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma.
Butaye E, Somers N, Grossar L, Pauwels N, Lefere S, Devisscher L, Raevens S, Geerts A, Meuris L, Callewaert N, Van Vlierberghe H, Verhelst X. Butaye E, et al. Among authors: van vlierberghe h. Aliment Pharmacol Ther. 2024 Jan;59(1):23-38. doi: 10.1111/apt.17748. Epub 2023 Oct 25. Aliment Pharmacol Ther. 2024. PMID: 37877758 Review.
An unusual cause of portal hypertension.
Ferdinande K, Lamiroy T, Hoorens A, Verhelst X, Degroote H, Raevens S, Van Vlierberghe H, Geerts A. Ferdinande K, et al. Among authors: van vlierberghe h. Acta Gastroenterol Belg. 2023 Jul-Sep;86(3):509-510. doi: 10.51821/86.3.11925. Acta Gastroenterol Belg. 2023. PMID: 37814574 Free article. No abstract available.
A remarkable presentation of a massive Budd-Chiari syndrome.
Ferdinande K, Degroote H, Geerts A, Van Vlierberghe H, Verhelst X, Raevens S. Ferdinande K, et al. Among authors: van vlierberghe h. Acta Gastroenterol Belg. 2023 Jul-Sep;86(3):503-504. doi: 10.51821/86.3.11994. Acta Gastroenterol Belg. 2023. PMID: 37814571 Free article. No abstract available.
Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
De Muynck K, Heyerick L, De Ponti FF, Vanderborght B, Meese T, Van Campenhout S, Baudonck L, Gijbels E, Rodrigues PM, Banales JM, Vesterhuus M, Folseraas T, Scott CL, Vinken M, Van der Linden M, Hoorens A, Van Dorpe J, Lefere S, Geerts A, Van Nieuwerburgh F, Verhelst X, Van Vlierberghe H, Devisscher L. De Muynck K, et al. Among authors: van vlierberghe h. Hepatology. 2024 Feb 1;79(2):269-288. doi: 10.1097/HEP.0000000000000557. Epub 2023 Aug 2. Hepatology. 2024. PMID: 37535809 Free PMC article.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
335 results